$10.3 Billion Merger
LOS ANGELES — Kite Pharma is selling itself too cheaply through an unfair process to Gilead Sciences, for $180 a share or $10.3 billion, shareholders say in a federal class action.
LOS ANGELES — Kite Pharma is selling itself too cheaply through an unfair process to Gilead Sciences, for $180 a share or $10.3 billion, shareholders say in a federal class action.